Keeping in view the detailed description of neurological disorders in 43 patients wit COVID-19, this retrospective review found whole neuraxis (plus cerebral vasculature) to be affected by COVID. Also, none of the autoantibodies observed in acute disseminated encephalomyelitis were linked with this infectious disease.

To completely understand the emerging spectrum of neurological ailments in COVID-19 patients via a weekly virtual COVID-19 neurology multi-disciplinary conference.

In early March 2020, this conference was held to discuss and begin to apprehend neurological presentations in COVID-19 patients assumed to have neurological ailments. Detailed clinical and paraclinical data were gathered from patients where the diagnosis of COVID-19 was confirmed through RNA Polymerase chain reaction (PCR), or where the diagnosis was probable and possible as per the WHO standards.

Twenty nine patients were COVID-19 PCR positive and definite, 8 probable and 6 possible, out of the total 43 patients included. The main groups emerged has been displayed in the following table:

The whole neuraxis (cerebral vasculature and response to immunotherapies in few patients) is affected due to the presence of SARS-CoV-2 infection. Of particular interest is the incidence of acute disseminated encephalomyelitis, mainly with the haemorrhagic change, not linked to COVID-19 severity. Future clinical, neuroradiological, biomarker and neuropathological studies are important to understand the causal pathobiological mechanisms for better management of this infection.